Weight loss drugs that work through glucagon-like peptide-1 (GLP-1) signalling have become widespread, yet they carry a metabolic cost that is only now being quantified: accelerated bone loss during the weight-loss phase. A competing hypothesis suggests that mitochondrial-derived peptides, particularly MOTS-c (mitochondrial open reading frame of the 12S rRNA-c), might preserve bone density through a fundamentally different mechanism. This article examines what current research shows about these two approaches, where the evidence is strongest, and where claims about bone preservation remain speculative.
The Misconception: MOTS-c as a Bone-Sparing Alternative to GLP-1
A growing narrative in longevity and metabolic health circles suggests that mitochondrial peptides like MOTS-c represent a superior path to weight loss because they preserve bone density while GLP-1 drugs do not. The implication is that MOTS-c works on bone through a distinct biological pathway, making it a direct competitor to GLP-1 therapy. This framing is appealing because it offers a solution to a real problem: GLP-1 drugs do appear to increase fracture risk in some populations during rapid weight loss. However, the evidence for MOTS-c as a bone-protective agent in humans is substantially thinner than the marketing around it suggests.
Where the Bone-Loss Problem Came From
The concern about GLP-1 drugs and bone emerged from post-hoc analysis of large randomized trials. In 2023, researchers analyzing data from the SUSTAIN-6 trial (semaglutide in type 2 diabetes) found that rapid weight loss was associated with increased fracture incidence, particularly in older adults. The mechanism is not mysterious: weight loss itself, independent of the drug used, triggers bone resorption because the skeleton adapts to reduced mechanical loading. GLP-1 drugs accelerate weight loss more aggressively than traditional interventions, which may compress the timeline for bone adaptation. Additionally, some evidence suggests GLP-1 signalling may directly suppress bone formation through effects on osteoblasts, though this remains debated in the literature. The bone loss is real, measurable, and clinically significant in certain subgroups (postmenopausal women, older adults with low baseline bone density).
What MOTS-c Actually Does: Mechanism vs. Clinical Effect
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome, discovered in 2015 by researchers at the University of Southern California. In cell culture and animal models, MOTS-c activates the AMPK-PGC1-alpha signalling axis, a pathway central to mitochondrial biogenesis and metabolic flexibility. A 2015 paper by Lee and colleagues in Cell Metabolism showed that MOTS-c administration improved glucose tolerance and insulin sensitivity in obese mice, partly through enhanced mitochondrial function. Subsequent work demonstrated that MOTS-c can increase energy expenditure and reduce fat accumulation in rodent models. The appeal is clear: if MOTS-c improves metabolism without forcing rapid weight loss, perhaps the skeleton would adapt more gracefully. But here is where mechanism does not imply clinical effect. No published randomized controlled trial in humans has measured bone density changes in response to MOTS-c. The peptide has never been tested in a head-to-head comparison with GLP-1 drugs. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.